Skip to main content

ACTIVASE rt-PA alteplase 100mg powder for solution for injection (Canada)

Section 19A approved medicine
ACTIVASE rt-PA alteplase 100mg powder for solution for injection (Canada)
Section 19A approval holder
Pro Pharmaceuticals Group Pty Ltd ABN 20 605 457 430
Phone
1300 077 674
Approved until
Status
Current
Medicines in short supply/unavailable
ACTILYSE alteplase (rch) 50 mg powder for injection vial with diluent vial - ARTG 17905
Indication(s)

ACTIVASE rt-PA (alteplase for injection) is indicated for:

  • The lysis of suspected occlusive coronary artery thrombi associated with evolving transmural myocardial infarction. Treatment should be initiated as soon as possible after the onset of acute myocardial symptoms.
  • The management of acute ischemic stroke (AIS) in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage.
Images
Picture of ACTIVASE rt-PA alteplase 100mg powder for solution for injection (Canada)

Help us improve the Therapeutic Goods Administration site